Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Metastatic Castrate Resistant Prostate Cancer
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Trial Timeline
Oct 15, 2025 → Dec 17, 2030
NCT ID
NCT07206056About Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)
Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC) is a phase 1/2 stage product being developed by Novartis for Progressive Metastatic Castrate Resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07206056. Target conditions include Progressive Metastatic Castrate Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07206056 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Progressive Metastatic Castrate Resistant Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AP01 | Avalyn Pharmaceuticals | Phase 2 | 44 |
| Enzalutamide + Placebo | Astellas Pharma | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| HRS-4357 injection + Enzalutamide；Abiraterone | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABBV-8E12 + Placebo solution for IV infusion on Day 15 | AbbVie | Phase 2 | 52 |
| Placebo + ABBV-8E12 | AbbVie | Phase 2 | 52 |
| ABBV-8E12 | AbbVie | Phase 1 | 33 |
| AZD4635 + Durvalumab + Cabazitaxel | AstraZeneca | Phase 2 | 52 |
| antisense oligonucleotide + placebo | Novartis | Phase 1 | 33 |
| Trametinib 2 mg | Novartis | Pre-clinical | 23 |
| Everolimus | Novartis | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| FTY720 + Placebo | Novartis | Phase 3 | 77 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Mayzent | Novartis | Pre-clinical | 23 |
| BAF312 + Placebo | Novartis | Phase 3 | 77 |
| Imatinib mesylate | Novartis | Approved | 85 |